Bisoprolol

Generic Name: Bisoprolol

Brand Names: Ziac

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₁NO_₄

CAS Number: 66722-44-9

Unique Ingredient Identifier: Y41JS2NL6U

Background: Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure. It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such as Carvedilol and Labetalol. It may be used alone or in combination with other drugs to manage hypertension and can be useful in patients with chronic obstructive pulmonary disease (COPD) due to its receptor selectivity.

Indication: Bisoprolol is indicated for the treatment of mild to moderate hypertension. It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.

Associated Conditions: Atrial Fibrillation, Cardiovascular Events, Chronic Stable Angina Pectoris, Heart Failure, Hypertension, Mild Hypertension, Premature Ventricular Contraction (PVC), Supraventricular Arrhythmias, Moderate Hypertension, Perioperative arrhythmia

Clinical Trials

Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab
Drug: Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab
Drug: Concor 5mg 2T and Crestor 20 mg 1Tab

First Posted Date: 2013-08-19

Last Posted Date: 2016-12-29

Lead Sponsor: HK inno.N Corporation

Registration Number: NCT01925300

Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension

Phase 4

Completed

Conditions: Untreated Essential Hypertension

Interventions: Drug: bisoprolol
Drug: atenolol

First Posted Date: 2013-01-07

Last Posted Date: 2013-01-08

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 109

Registration Number: NCT01762436

Locations: 🇨🇳
State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension and Department of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition

Phase 1

Completed

Conditions: Fed

Interventions: Drug: Bisoprolol Fumarate Tablet 10 mg
Drug: Bisoprolol

First Posted Date: 2012-12-07

Last Posted Date: 2012-12-07

Lead Sponsor: IPCA Laboratories Ltd.

Target Recruit Count: 24

Registration Number: NCT01744873

Locations: 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Ahmedabad, Gujarat, India

Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition

Phase 1

Completed

Conditions: Fasting

Interventions: Drug: Bisoprolol Fumarate Tablet 10 mg
Drug: Bisoprolol

First Posted Date: 2012-12-05

Last Posted Date: 2012-12-05

Lead Sponsor: IPCA Laboratories Ltd.

Target Recruit Count: 24

Registration Number: NCT01741623

Locations: 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Ahmedabad, Gujarat, India

HaemoDYNAMICs in Primary and Secondary Hypertension

Recruiting

Conditions: Primary Hypertension
Secondary Hypertension
Renal Insufficiency
Aortic Stenosis

Interventions: Drug: Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)
Dietary Supplement: Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)
Drug: Salbutamol 400 µg (single dose, no longer given since January 2017)
Drug: L-arginine (10 min infusion, no longer given since January 2017)
Drug: Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)
Dietary Supplement: Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)

First Posted Date: 2012-12-05

Last Posted Date: 2021-08-19

Lead Sponsor: Tampere University

Target Recruit Count: 2000

Registration Number: NCT01742702

Locations: 🇫🇮
Tampere University Hospital, Tampere, Southern Finland, Finland
🇫🇮
Tampere University, Tampere, Southern Finland, Finland

Beta Blocker Therapy in Moderate to Severe COPD

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Carvedilol
Drug: Bisoprolol
Drug: Beclometasone/formoterol
Drug: Tiotropium
Drug: Beclometasone

First Posted Date: 2012-08-02

Last Posted Date: 2019-04-23

Lead Sponsor: University of Dundee

Target Recruit Count: 18

Registration Number: NCT01656005

Locations: 🇬🇧
Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom

Effect of Bisoprolol on Progression of Aortic Stenosis

Phase 4

Terminated

Conditions: Aortic Stenosis

Interventions: Drug: placebo
Drug: bisoprolol

First Posted Date: 2012-04-17

Last Posted Date: 2018-06-27

Lead Sponsor: Asan Medical Center

Target Recruit Count: 20

Registration Number: NCT01579058

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of